Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 17;54:101754. doi: 10.1016/j.eclinm.2022.101754

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 5 — Cumulative fraction of cervical cancer cases averted after HPV vaccination and cervical cancer screening – among all women and among WLHIV: Age-standardized fraction of cumulative cervical cancer cases averted over time since 2020 following girls' vaccination only (Sc1), girls' vaccination + 1 lifetime cervical screen (Sc2), girls' vaccination + 2 lifetime cervical screen (Sc3) in panels A–B, F-G, and Sc1 + vaccination of young WLHIV (Sc4), Sc3+ 3-yearly screening of WLHIV (Sc4), or Sc3 + vaccination and 3-yearly screening of WLHIV (sc6) in panels C–E, H-J. Results are presented among all women (A–E) and among WLHIV (F–J). The relevant scenarios are compared to basecase (A, C, F, H), girls' vaccination alone (B, D, G, I), and girls' vaccination plus 2 lifetime cervical screens (E, J). The numbers represent the median of the three models. The error bars represent the minimum and maximum of the three models. Vaccine coverage = 90%, Vaccine efficacy = 100% against HPV-16/18/31/33/45/52/58, Vaccine duration = Lifetime; Screening = HPV testing, Screening uptake = 45% (2023–2029), 70% (2030–2044), 90% (2045+). Treatment efficacy = 100%, Lost to follow-up = 10%. Scenarios are as described in Table 1.

Fig. 5 — Cumulative fraction of cervical cancer cases averted after HPV vaccination and cervical cancer screening – among all women and among WLHIV: Age-standardized fraction of cumulative cervical cancer cases averted over time since 2020 following girls' vaccination only (Sc1), girls' vaccination + 1 lifetime cervical screen (Sc2), girls' vaccination + 2 lifetime cervical screen (Sc3) in panels A–B, F-G, and Sc1 + vaccination of young WLHIV (Sc4), Sc3+ 3-yearly screening of WLHIV (Sc4), or Sc3 + vaccination and 3-yearly screening of WLHIV (sc6) in panels C–E, H-J. Results are presented among all women (A–E) and among WLHIV (F–J). The relevant scenarios are compared to basecase (A, C, F, H), girls' vaccination alone (B, D, G, I), and girls' vaccination plus 2 lifetime cervical screens (E, J). The numbers represent the median of the three models. The error bars represent the minimum and maximum of the three models. Vaccine coverage = 90%, Vaccine efficacy = 100% against HPV-16/18/31/33/45/52/58, Vaccine duration = Lifetime; Screening = HPV testing, Screening uptake = 45% (2023–2029), 70% (2030–2044), 90% (2045+). Treatment efficacy = 100%, Lost to follow-up = 10%. Scenarios are as described in Table 1.